Loading
Brazilian women treated for breast cancer in the public health system were more often found with advanced disease and less often through screening than women with private insurance.
AMAZONA III is a prospective cohort at 23 Brazilian sites of women newly diagnosed with invasive breast cancer from January 2016 to March 2018. Of 2,950 patients, median age 53.9, 63.1 per cent were treated in the public system. Most (68.6 per cent) had stage II to III disease. Luminal A-like was the commonest subtype (48.0 per cent), followed by luminal B HER2-positive-like (17.0) and triple-negative (15.6). Only 34 per cent were diagnosed by screening.
In Brazil the same disease is found later in the public system, which treats most women. The authors note that Brazil's cancer registries are limited in number and quality, which is why a cohort like this is needed to see it.
Shares Daniela Dornelles Rosa, AMAZONA III: prospective evaluation of breast cancer at Brazilian institutions (GBECAM 0115), Latin American Cooperative Oncology Group, Carlos Barrios.
Shares Daniela Dornelles Rosa, Latin American Cooperative Oncology Group, Carlos Barrios, HR-positive / HER2-negative breast cancer.
Shares A.C. Camargo Cancer Center, Instituto Nacional de Câncer (INCA).
Shares Carlos Barrios, HR-positive / HER2-negative breast cancer.
Shares Carlos Barrios, HR-positive / HER2-negative breast cancer.
Shares Carlos Barrios, HR-positive / HER2-negative breast cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/